Advertisement

Topics

PubMed Journals Articles About "Methylphenidate And Parkinson's Disease" - Page: 2 RSS

08:29 EST 15th December 2018 | BioPortfolio

Methylphenidate And Parkinson's Disease PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Methylphenidate And Parkinson's Disease articles that have been published worldwide.

More Information about "Methylphenidate And Parkinson's Disease" on BioPortfolio

We have published hundreds of Methylphenidate And Parkinson's Disease news stories on BioPortfolio along with dozens of Methylphenidate And Parkinson's Disease Clinical Trials and PubMed Articles about Methylphenidate And Parkinson's Disease for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Methylphenidate And Parkinson's Disease Companies in our database. You can also find out about relevant Methylphenidate And Parkinson's Disease Drugs and Medications on this site too.

Showing "Methylphenidate Parkinson Disease" PubMed Articles 26–50 of 22,000+

Dopaminergic degeneration induces early posterior cortical thinning in Parkinson's disease.

Cognitive decline in Parkinson's disease (PD) is a highly prevalent condition with no effective treatment. Cortical atrophy is thought to promote its development but to design optimal therapeutic approaches in this clinical setting we need to understand the physiopathological mechanisms leading to this disorder.


Parkinson's disease across ethnicities: A nationwide study in New Zealand.

New Zealand is an ethnically diverse country with a unified national prescribing system. This provides a good framework to use drug-tracing methodology to establish the prevalence and incidence of Parkinson's disease across different ethnic groups. The objective of this study was to determine the prevalence and incidence of Parkinson's disease in the major ethnic groups in New Zealand.

The Functional Alterations in Top-Down Attention Streams of Parkinson's disease Measured by EEG.

Early and moderate Parkinson's disease patients seem to have attention dysfunctions manifested differentially in separate attention streams: top-down and bottom-up. With a focus on the neurophysiological underpinnings of such differences, this study evaluated source-localized regional activity and functional connectivity of regions in the top-down and bottom-up streams as well as any discordance between the two streams. Resting state electroencephalography was used for 36 Parkinson's disease patients and 36...


GAPDH rs1136666 SNP indicates a high risk of Parkinson's disease.

Development of Parkinson's disease (PD) is attributed to both genetic and environmental factors. Furthermore,GAPDH may play a key role in the development of neurodegenerative disease. Examination of genetic polymorphism in patients with sporadic PD will help uncover the mechanisms of PD pathogenesis and provide new insights into the treatment of PD.

Pallidal beta bursts in Parkinson's disease and dystonia.

Exaggerated beta power has been discussed as a disease-specific biomarker for Parkinson's disease (PD) and has recently been suggested to rely on prolonged bursts of subthalamic beta synchronization.

Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson's disease.

Currently, no reliable predictors of cognitive impairment in Parkinson's disease exist. We hypothesized that microstructural changes at grey matter T1-weighted MRI and diffusion tensor imaging in the cholinergic system nuclei and associated limbic pathways underlie cognitive impairment in Parkinson's disease. We performed a cross-sectional comparison between patients with Parkinson's disease with and without cognitive impairment. We also performed a longitudinal 36-month follow-up study of cognitively intac...

Magnetic resonance T1w/T2w ratio: A parsimonious marker for Parkinson's disease.

Newer MRI techniques have shown promise in capturing early Parkinson's disease (PD)-related changes in the substantia nigra pars compacta (SNc), the key pathological loci. Their translational value, however, is hindered by technical complexity and inconsistent results.

Non-motor features of Parkinson's disease in a nested case-control study of US men.

Several non-motor features may individually contribute to identify prodromal Parkinson's disease (PD), but little is known on how they interact.

Distinctive Olfactory Pattern in Parkinson's Disease and Non-Neurodegenerative Causes of Hyposmia.

Olfactory dysfunction is common in Parkinson's disease (PD). The characteristics of the hyposmia in PD have not been well defined.

The genetic association between apolipoprotein E gene polymorphism and Parkinson disease: A meta-Analysis of 47 studies.

Although the relationship between apolipoprotein E (ApoE) gene polymorphisms and the risk of Parkinson disease (PD) has been established, the results were inconsistent and inconclusive.

Clinical, electrophysiological, and imaging study in essential tremor-Parkinson's disease syndrome.

Essential tremor-Parkinson's disease (ET-PD) syndrome is a clinical condition in which individuals with a long-lasting history of Essential tremor (ET) eventually develop Parkinson's disease (PD). The aim of the study was to investigate the accuracy performances of clinical, neurophysiological, and imaging biomarkers in differentiating patients affected by ET-PD syndrome from patients with ET or PD.

The hidden side of Parkinson's disease: studying pain, anxiety and depression in animal models.

Parkinson's disease is a neurodegenerative disease leading to the loss of midbrain dopamine neurons. It is well known and characterized by motor symptoms that are secondary to the loss of dopamine innervation, but it is also accompanied by a range of various non-motor symptoms, including pain and psychiatric disorders such as anxiety and depression. These non-motor symptoms usually appear at early stages of the disease, sometimes even before the first motor symptoms, and have a dramatic impact on the qualit...

The relationship of anxious and depressive symptoms in Parkinson's disease with voxel-based neuroanatomical and functional connectivity measures.

Anxiety and depression are two frequent comorbidities of Parkinson's disease (PD). However, the underlying neural mechanism is still unclear and the studies on their neural correlates were insufficient.

Automated Systems Based on Wearable Sensors for the Management of Parkinson's Disease at Home: A Systematic Review.

Parkinson's disease is a common neurodegenerative pathology that significantly influences quality of life (QoL) of people affected. The increasing interest and development in telemedicine services and internet of things technologies aim to implement automated smart systems for remote assistance of patients. The wide variability of Parkinson's disease in the clinical expression, as well as in the symptom progression, seems to address the patients' care toward a personalized therapy.

Utilization of Chinese Herbal Medicine and its Association with the Risk of Fracture in Patients with Parkinson's Disease in Taiwan.

Traditional Chinese medicine (TCM) has been used for over two thousand years to treat motor impairments corresponding to the clinical manifestations of Parkinson's disease (PD).

Occupational stress and risk for Parkinson's disease: A nationwide cohort study.

Stress has been suggested as a contributing factor in the etiology of Parkinson's Disease (PD), but epidemiological evidence is sparse.

Effects of Parkinson's disease and dopamine on digit span measures of working memory.

Parkinson's disease (PD) impairs working memory (WM)-the ability to maintain items in memory for short periods of time and manipulate them. There is conflicting evidence on the nature of the deficits caused by the disease, and the potential beneficial and detrimental effects of dopaminergic medication on different WM processes.

Towards an automatic evaluation of the dysarthria level of patients with Parkinson's disease.

Parkinson's disease (PD) is a neurological disorder that produces motor and non-motor impairments. The evaluation of motor symptoms is currently performed following the third section of the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS-III); however, only one item of that scale is related to speech impairments. It is necessary to develop a specific scale such that considers those aspects related to speech impairments of the patients.

Performance analysis of different classification algorithms using different feature selection methods on Parkinson's disease detection.

In diagnosis of neurodegenerative diseases, the three-dimensional magnetic resonance imaging (3D-MRI) has been heavily researched. Parkinson's disease(PD) is one of the most common neurodegenerative disorders.

Is the Munich dysphagia Test-Parkinson's disease (MDT-PD) a valid screening tool for patients at risk for aspiration?

Dysphagia is common in Parkinson's disease (PD) and leads to pneumonia, malnutrition, and reduced quality of life. For detecting dysphagia-exposed PD patients, the Munich dysphagia test-Parkinson's disease (MDT-PD) is a patient self-reported tool that has been developed specifically for PD patients. The MDT-PD is available in both German and English. This study aimed to ascertain whether the MDT-PD can detect aspiration in PD patients and, therefore, serve as a suitable screening tool.

Multimorbidity Predicts Quality of Life but not Motor Severity in Early Parkinson's Disease.

Recent guidance by the National Institute for Health and Care Excellence (NICE) focuses on the management of people with multimorbidity, including Parkinson's disease (PD). To date there has been little exploration of this in neurodegenerative diseases. This study aimed to explore the associations between multimorbidity, motor severity and quality of life (QoL) in early PD. Regression analyses determined whether multimorbidity was significantly associated with disease severity and QoL. Multimorbidity was a ...

Computational prediction of changes in brain metabolic fluxes during Parkinson's disease from mRNA expression.

Parkinson's disease is a widespread neurodegenerative disorder which affects brain metabolism. Although changes in gene expression during disease are often measured, it is difficult to predict metabolic fluxes from gene expression data. Here we explore the hypothesis that changes in gene expression for enzymes tend to parallel flux changes in biochemical reaction pathways in the brain metabolic network. This hypothesis is the basis of a computational method to predict metabolic flux changes from post-mortem...

Phenylalanine-mediated Porous CuxO Nanoparticle Clusters Ameliorate Parkinson's Disease by Reducing Oxidative Stress.

Reactive oxygen species (ROS)-mediated mitochondrial dysfunction is one of the major pathological mechanisms of Parkinson's disease. Using inorganic nanomaterials to scavenge ROS has drawn significant interest and can prevent ROS-mediated neurological disorders. We prepared uniform CuxO nanoparticle clusters (NCs) with an average size of 65 ± 7 nm, using phenylalanine (Phe) as the structure-directing agent. These CuxO NCs functionally mimicked the activities of peroxidase, superoxide dismutase, catalase, a...

Pattern Analysis of Computer Keystroke Time Series in Healthy Control and Early-Stage Parkinson's Disease Subjects using Fuzzy Recurrence and Scalable Recurrence Network Features.

Identifying patients with early stages of Parkinson's disease (PD) in a home environment is an important area of neurological disorder research, because it is of therapeutic and economic benefits to optimal intervention and management of the disease.

Effects of Long-Term Use of Prescription Methylphenidate on Myocardial Performance in Children with Attention-Deficit/Hyperactivity Disorder: A Tissue Doppler Imaging Study.

Many children diagnosed with attention-deficit/hyperactivity disorder are treated with methylphenidate (MPH). The purpose of this study was to evaluate the relationship between long-term use of osmotic-release oral system methylphenidate (OROS MPH) and cardiac functions.


Advertisement
Quick Search
Advertisement
Advertisement